Aprepitant Anticipation:
This was the first drug to be approved as a Tachykinin
antagonist.52Since then this has been tried in
numerous clinical trials for numerous indications. There are various
trials that have tried the role of aprepitant as an antiemetic drug for
the treatment of highly emetogenic conditions like following cancer
chemotherapy and some following surgical procedures for PONV. The trial
done with aprepitant in HIV infected individuals showed no viral load
reduction despite reduction in biological activity.71A
few trials were successful but for many trials the information was not
available and some were terminated. Aprepitant was tried in germ cell
tumours and was found to have a complete remission rate as compared to
placebo (NCT00572572). Another study that involved aprepitant in its
well-known indication for CINV following cisplatin chemotherapy
(NCT00619359). Again, trials involving Aprepitant in PONV and with other
drugs like granisetron, dexamethasone, prochlorperazine and palonosetron
(NCT00475085 and NCT00819039) showed it to be an effective drug for
antiemesis, but still its effect in other indications is still in the
line and yet to be established this might become feasible in the near
future if research continues to flourish.
Table 3